Chronic Lymphocytic Leukemia News and Research

RSS

Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.

Why patients with ALL relapse after CAR-T cell therapy

Researchers have made a new discovery about a rare mechanism that triggers the relapse of acute lymphoblastic leukemia (ALL) after CAR T cell therapy.

1 Oct 2018

Why patients with ALL relapse after CAR-T cell therapy

Researchers have made a new discovery about a rare mechanism that triggers the relapse of acute lymphoblastic leukemia (ALL) after CAR T cell therapy.

1 Oct 2018

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, today announced that it has been selected by Verastem OncologyTM to dispense COPIKTRA (duvelisib) capsules.

28 Sep 2018

$CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL$

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

AbbVie, a research-based global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion for VENCLYXTO® in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia who have received at least one prior therapy.

21 Sep 2018

New study links stress with biological disease markers in leukemia patients

Patients with chronic lymphocytic leukemia who feel more stress also have more cancer cells in their blood and elevated levels of three other markers of more advanced disease.

12 Sep 2018

Verastem doses first patient in Phase I/II clinical trial of duvelisib in combination with venetoclax

Verastem, Inc., operating as Verastem Oncology, a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced dosing of the first patient in a multicenter Phase I/II clinical trial at the Dana-Farber/Harvard Cancer Center of duvelisib in combination with venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

6 Sep 2018

Researchers launch clinical trial to assess new drug combination against metastatic breast cancers

Researchers at University of California San Diego School of Medicine have launched a phase Ib clinical trial to assess the safety and tolerability of cirmtuzumab, in combination with standard chemotherapy, to treat metastatic or locally advanced breast cancer that cannot be surgically removed.

28 Aug 2018

Patients with chronic lymphocytic leukemia have higher risk of melanoma, shows study

While studying a large group of individuals with chronic lymphocytic leukemia, a Wilmot Cancer Institute scientific team made an important discovery -- these patients had a sizable 600 percent higher risk of melanoma, the most dangerous form of skin cancer.

10 Aug 2018

Portfolio diet reduces risk factors for cardiovascular disease

University of Toronto researchers have found that the portfolio diet, a plant-based way of eating previously shown to lower cholesterol levels, reduces other risk factors for cardiovascular disease including blood pressure, triglycerides and inflammation.

27 Jul 2018

AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia

AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for venetoclax in combination with a hypomethylating agent or in combination with low-dose cytarabine for the treatment of newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.

20 Jul 2018

Inflection Biosciences' dual mechanism inhibitor shows promise as treatment for CLL

Inflection Biosciences Ltd, a private company developing innovative therapeutics for cancer, today announced the publication of preclinical data showing the company's dual mechanism PIM/PI3 kinase inhibitor IBL-202 has promise as a treatment for chronic lymphocytic leukemia.

17 Jul 2018

Homogenous BTK occupancy assay used in tirabrutinib clinical studies

In a new SLAS Discovery article, Helen Yu and a team of researchers at Gilead Sciences, Inc. present a time-resolved fluorescence resonance energy transfer-based Bruton's tyrosine kinase occupancy assay that can measure target engagement in peripheral blood mononuclear cells and in lymph-node and bone-marrow samples.

17 Jul 2018

New findings refine link between clonal hematopoiesis and blood cancer risk

It's a common occurrence in elderly people: Blood cells carrying mutated DNA explosively increase in number, resulting in genetic "mosaicism": the presence of a population of cells that carries an altered genome.

12 Jul 2018

Phase I trial shows safety of investigational drug in treating chronic lymphocytic leukemia

Reporting results from a first-in-human phase I clinical trial, researchers at University of California San Diego School of Medicine have found that treatment with cirmtuzumab, an experimental monoclonal antibody-based drug, measurably inhibited the "stemness" of chronic leukemia cancer cells - their ability to self-renew and resist terminal differentiation and senescence.

1 Jun 2018

Researchers complete genomic map of chronic lymphocytic leukemia

Researchers have created a high-resolution map of the entire epigenome of chronic lymphocytic leukemia, the most common form of leukemia.

23 May 2018

Celgene to share new and updated data around novel hematological therapies

Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.

22 May 2018

Researchers test new cancer research model that may reduce cost and speed up studies

A new model for improving how clinical trials are developed and conducted by bringing together academic cancer experts and pharmaceutical companies is being tested by research experts at The University of Texas MD Anderson Cancer Center.

15 May 2018

New T cell biomarker could be much-needed patient-selection tool for CAR T cell therapy

Penn Medicine researchers may have found the reason why some patients with advanced chronic lymphocytic leukemia don't respond to chimeric antigen receptor T cell therapy, and the answer is tied to how primed patients' immune systems are before the therapy is administered.

30 Apr 2018

Two immune checkpoint inhibitors efficiently block leukemia development in preclinical tests

Chronic lymphocytic leukemia is a hematological malignancy that originates in the blood-forming cells of the bone marrow and spreads to other organs through the bloodstream.

17 Apr 2018

Research reveals immune suppressive role of soluble antibodies in tumor progression

Wistar researchers have found that soluble antibodies promote tumor progression by inducing accumulation of myeloid-derived suppressor cells (MDSCs) in pre-clinical cancer models. Results were published online in Cancer Immunology Research.

13 Apr 2018

Chronic Lymphocytic Leukemia News and Research

Further Reading

Why patients with ALL relapse after CAR-T cell therapy

Why patients with ALL relapse after CAR-T cell therapy

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

New study links stress with biological disease markers in leukemia patients

Verastem doses first patient in Phase I/II clinical trial of duvelisib in combination with venetoclax

Researchers launch clinical trial to assess new drug combination against metastatic breast cancers

Patients with chronic lymphocytic leukemia have higher risk of melanoma, shows study

Portfolio diet reduces risk factors for cardiovascular disease

AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia

Inflection Biosciences' dual mechanism inhibitor shows promise as treatment for CLL

Homogenous BTK occupancy assay used in tirabrutinib clinical studies

New findings refine link between clonal hematopoiesis and blood cancer risk

Phase I trial shows safety of investigational drug in treating chronic lymphocytic leukemia

Researchers complete genomic map of chronic lymphocytic leukemia

Celgene to share new and updated data around novel hematological therapies

Researchers test new cancer research model that may reduce cost and speed up studies

New T cell biomarker could be much-needed patient-selection tool for CAR T cell therapy

Two immune checkpoint inhibitors efficiently block leukemia development in preclinical tests

Research reveals immune suppressive role of soluble antibodies in tumor progression

One Health, One Mission: The World Organisation for Animal Health on the AMR Frontline

Uniting Against Resistance: The World Health Organization for World Antimicrobial Awareness Week 2023

Tackling Antimicrobial Resistance: A Conversation with Dr. Beverley Isherwood

Latest News